Ulocuplumab
Ulocuplumab
Ulocuplumab (pronounced: yoo-loh-KYOO-ploo-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of immunotherapy that targets the CXCR4 protein, which is overexpressed in many types of cancer.
Etymology
The name "Ulocuplumab" follows the INN naming convention for monoclonal antibodies. The "-mab" suffix indicates it is a monoclonal antibody, while the "u-" prefix is used for human sources. The "locu-" stem is used for immunomodulating antibodies, and the "pl-" infix is used for the lymphocytes.
Mechanism of Action
Ulocuplumab works by binding to the CXCR4 protein on the surface of cancer cells. This prevents the cancer cells from interacting with their environment, which can help to slow down or stop the growth of the cancer.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Immunotherapy: A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.
- CXCR4: A protein that is often overexpressed in cancer cells and is the target of Ulocuplumab.
- Lymphocyte: A type of white blood cell that is part of the immune system.
External links
- Medical encyclopedia article on Ulocuplumab
- Wikipedia's article - Ulocuplumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski